Want to get a taste of what our 30-minute webinars are about? Check out our available replays (no sign-up required!) bit.ly/4aqII6p #oncology #hematology #meded

Join Dr. Steve McCune as he reviews extended clinical trial data for an I-O-based regimen used in patients used across certain metastatic gastroesophageal cancers. Register Now! bit.ly/3UpIx6A #Oncology

Join Dr Harry Erba for a review of updates in the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) on April 17th. This presentation also includes recent data release from ASH. bit.ly/3UjZ77O #hematology #Oncology

Join Dr Flowers for a treatment update on follicular #lymphoma . He'll review ROSEWOOD data for the BTK inhibitor zanubrutinib in the treatment of relapsed/refractory follicular lymphoma and discuss potential implications on patient care. Sign up now! bit.ly/4aIARlm

Join us on April 3 for this live webinar on ESR1 Mutations in Recurrent HR+ HER2- Breast Cancer: Testing and Treatment - including recent data releases from #ESMO and #SABCS . Register now bit.ly/3xuBqR9 #Oncology

Join us for Best Practices for Specimen Acquisition, Stewardship, and Staging for Biomarker Testing in Non-Small Cell Lung Cancer. Grab your seat now for the March 27 live webinar! bit.ly/3TRNmoQ #oncology #NSCLC

Interpret recent clinical trials that led to the approval of I-O agents, including 1L combination therapies for the management of metastatic melanoma. Claim your seat! bit.ly/3TK59ys #oncology #hematology

Don't miss this opportunity to understand the rationale and guidelines supporting ESR1 mutation testing in patients with HR+ HER2- recurrent #breastcancer . bit.ly/49Ko7u4 #oncology #MedEd

Treating patients with cholangiocarcinoma? Join us Feb 28 to learn more! bit.ly/3TdGiCA #Oncology

Join Dr Whitman as he will discuss key questions and ongoing results from clinical trials, along with providing expert guidance and recommendations. Sign up now! bit.ly/49bFi7L #oncology #hematology

Dr. Kasbari will discuss recent clinical data for the application of an emerging treatment for ROS1-positive NSCLC. Register now! bit.ly/4bFby4P #NSCLC #LCSM #oncology

Understand the DUAL IO treatment options for metastatic Melanoma. Register now! bit.ly/49bFi7L #oncology #hematology

Join us for a review of the recent clinical trial that led to FDA approval of a ROS1+ non-small cell lung cancer treatment. Save your spot! bit.ly/4bFby4P #LCSM #NSCLC #oncology

Join Dr. Jorge Cortes on Feb. 14 for a review of the emerging data on the use of targeted therapy for patients with relapsed/refractory acute myeloid leukemia with IDH1 mutations including data presented at #ash2023 ! bit.ly/3HVfwZq #oncology #hematology

Have you seen our February event calendar? It's jam-packed with short, informative (and free) webinars that provide busy #healthcareprofessionals insight into recent clinical advances and treatment options. Check it out 👀 bit.ly/42uvHXd #oncology #hematology #meded

Join us as Dr. Kasbari will discuss recent clinical data for the application of an emerging treatment for ROS1-positive NSCLC. Sign up now! bit.ly/3UnNBsw #NSCLC #LCSM #oncology

Learn about the recent clinical trial that led to FDA approval of a ROS1+ non-small cell lung cancer treatment. Grab your spot! bit.ly/3UnNBsw #LCSM #NSCLC #Oncology

10-minute #podcast - Gain insight into current and emerging data for treating EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer, including updates from ESMO 2023. bit.ly/3RmKVcO #oncology #NSCLC

Join us on Jan. 24 to gain insight on TRUQAP + fulvestrant: A Novel 2L Treatment Option for HR+/HER2- aBC or mBC With PIK3CA/AKT1/PTEN Alterations. Register Now! bit.ly/47UilVm #breastcancer #Oncology #hematology

Join us on Jan. 18th for Conversations in Hematology - Post-ASH Updates in CLL. Grab your seat now! bit.ly/4223mao #hematology #oncology